



## Stress Ulcer Prophylaxis in the Intensive Care Unit

### Information for nursing staff

Your department enrolls patients in  
the SUP-ICU trial

**The SUP-ICU trial compares pantoprazole and placebo as stress ulcer prophylaxis for critically ill patients**

**The SUP-ICU trial enrolls 3350 patients at intensive care units in Europe**

**The SUP-ICU trial is supported by governmental funding and is approved by all relevant authorities**

#### Queries? Please contact:

Søren Marker Jensen, coordinating investigator  
[soeren.marker.jensen.01@regionh.dk](mailto:soeren.marker.jensen.01@regionh.dk)  
Phone: +45 3545 7450

Morten Hylander Møller, sponsor  
[Mortehylander@gmail.com](mailto:Mortehylander@gmail.com)  
Phone: +45 3545 8685



## The nurse's role in SUP-ICU

### New patients in the department

A large number of adults acutely admitted to the ICU will be eligible for inclusion in the SUP-ICU trial. Please remind clinicians that they have to consider enrolment of the patient in the trial before prescribing stress ulcer prophylaxis (e.g. pantoprazole, omeprazole, ranitidine and cimetidine) for the patient.

### Daily administration of trial medication

During ICU stay the trial medication has to be given once daily (maximum 90 days).

### Daily allocation of trial medication

**The clinician randomising the patient has received the first vial identifier number when randomising the patient. Go directly to 10 if it is the first dose.**

1. Visit [www.sup-icu.com](http://www.sup-icu.com)
2. Click 'Trial medication'
3. Login with the shared login of your department
4. Mark the patient at the list
5. Write your name in the box
6. Click 'Dispense vial to participant'
7. Confirm
8. The vial identifier number will appear
9. You have the option to print the number
10. Add 10 ml sodium chloride 0.9% to the vial, agitate gently and administer the medication to the patient as usual.

**A detailed manual with pictures is available at [www.sup-icu.com](http://www.sup-icu.com)**

Please ask the clinician to prescribe the trial medication in the medication chart/ICU chart as 'SUP-ICU trial medication intravenously once daily' (if possible).

Aside from trial medication patient management will be otherwise unaffected.

## Information about SUP-ICU

### Background

Critically ill patients are at risk of developing gastrointestinal bleeding and stress ulcer prophylaxis (SUP) is recommended. However, the evidence supporting prevention of stress related gastrointestinal bleeding is lacking. Furthermore, research has indicated that SUP may increase the risk of pneumonia, clostridium difficile infection and cardiovascular complications.

The aim of the SUP-ICU trial is to assess benefits and harms of SUP with pantoprazole for adult critically ill patients in the ICU and hereby improve the evidence base for the use of SUP in the ICU.

### Methods

A total of 3350 patients in ICUs in Europe will be randomised to receive

#### **either**

- Pantoprazole 40 mg (added 10 ml of sodium chloride 0.9%)

#### **or**

- Placebo (sterile air filled vial added 10 ml sodium chloride 0.9%)

Aside from trial medication patient management will be otherwise unaffected

### Results

At the end of the trial we will assess mortality and the incidence of gastrointestinal bleeding, pneumonia, clostridium difficile infection and cardiovascular complications in the two groups.

### Funding

The trial has a budget at 17 million Danish kroner (2.3 mil Euro) and is funded by governmental funding (Innovation Fund Denmark)

**The full protocol is available at [www.sup-icu.com](http://www.sup-icu.com)**

## Instructions

Trial instructions and other relevant documents are available at [www.sup-icu.com](http://www.sup-icu.com) (Trial documents)

## Queries?

If you have any queries please do not hesitate to contact coordinating investigator Søren Marker Jensen. See contact information at the back of this leaflet.

**Do you need help?  
Call the SUP-ICU Hotline  
+45 3545 7450  
Available 24/7  
OR  
[soeren.marker.jensen.01@regionh.dk](mailto:soeren.marker.jensen.01@regionh.dk)**